Reviews/Dry Eye Disease Treatment/Lifitegrast reduces inferior corneal staining
Lifitegrast · DED-LIFT-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Two separate randomized trials that compared lifitegrast 5% against an inactive drop set out specifically to measure staining in the lower part of the cornea, and both found less staining with the drug ([1], [11]). A third large randomized trial built around the same lower-cornea measurement, however, found no difference between the drug and the inactive drop ([3]). A later re-analysis that pooled trial data found the clearest benefit in patients who started with more severe lower-cornea staining ([2]). Several smaller clinics-and-charts studies reported improvement in overall corneal staining, but they had no comparison group and did not isolate the lower cornea ([6], [7], [9]). The panel treated the two matching positive trials and the pooled analysis as the stronger body of evidence, while the one well-sized trial that showed nothing kept it from going higher.
On the exact endpoint named by the claim — inferior corneal staining score (ICSS) — the corpus holds three pivotal randomized controlled trials: [1] met ICSS as its primary sign endpoint (P=0.0007), [11] met ICSS as its primary endpoint (P=0.027), and [3] (OPUS-2) had ICSS as a co-primary endpoint and did not meet it (treatment effect 0.03; 95% CI -0.10 to 0.17; P=0.6186). A pooled post-hoc responder analysis of OPUS-2 and OPUS-3 data [2] found composite sign-and-symptom response favouring lifitegrast, strongest in the subgroup with baseline ICSS greater than 1.5. Uncontrolled supportive studies reported reductions in total or general corneal staining ([6] 1.42 to 0.39, P=0.006; [9] -0.15, P=0.007) but did not isolate the inferior region. The direct randomized evidence on the precise endpoint is therefore split: two positive pivotal trials against one null pivotal trial. The contested point: The division is whether a well-powered randomized trial ([3], N=718) that flatly failed the exact inferior-staining endpoint (P=0.6186) should block an unconditional claim, or whether two positive pivotal trials on the same endpoint ([1], [11]) and a pooled analysis [2] carry the direction. The positive replications are also uneven: [1] is strong (P=0.0007) while [11] sits nearer the significance floor (P=0.027) with its larger inferior-region effect resting on a post-hoc subgroup (P=0.046).
All 11 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
OPUS-2 [3], an adequately powered RCT, flatly failed the exact inferior corneal staining endpoint (effect 0.03; 95% CI -0.10 to 0.17; P=0.6186) — a direct contradiction that an unconditional claim overreaches.
The positive replications are modest: [11]'s P=0.027 is near the significance floor and its larger inferior-region effect rests on a post-hoc subgroup (P=0.046), not a confirmatory endpoint.
Where it remains uncertain. The pivotal OPUS-2 RCT [3] had inferior corneal staining as a co-primary endpoint and failed it (treatment effect 0.03; 95% CI -0.10 to 0.17; P=0.6186).
Aleatory
[11]'s primary result (P=0.027) and its inferior-region subgroup (P=0.046) sit close to conventional significance, so sampling variability could plausibly move them.
Epistemic
Two pivotal RCTs ([1], [11]) met the ICSS endpoint while one adequately powered pivotal RCT [3] did not (P=0.6186); the corpus does not resolve why they disagree.
Inferential
Inferior corneal staining is an ocular-surface damage score, not a patient hard outcome, so the clinical meaning of the measured change is an inference beyond the corpus.
The load-bearing papers from a corpus of 11, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT positive on the exact ICSS endpoint.
“The study met the primary objective efficacy ICSS end point in demonstrating superiority of lifitegrast compared with placebo (P = 0.0007).”
Panel auditInternal validity: high · scope of inference: Adults with dry eye disease treated twice daily for 84 days; directly addresses inferior corneal staining change vs placebo.Key limitations: industry-style efficacy trial · single 84-day timepoint for primary
Pooled post-hoc analysis locating the ICSS sign benefit in higher-baseline-severity patients.
“the subgroup with ICSS of greater than 1.5 and EDS of at least 60 at baseline (ie, moderate to severe DED) demonstrated a 1.70- to 2.11-fold higher odds of achieving clinically meaningful improvement with lifitegrast across all sign and symptom end point pairs (P ≤ .001).”
Panel auditInternal validity: medium · scope of inference: Moderate-to-severe DED participants; likelihood of clinically meaningful ICSS improvement rather than mean staining change.Key limitations: post hoc analysis · responder/composite metric not direct mean ICSS · overlaps with OPUS-2/OPUS-3 source trials
Pivotal RCT null on the exact ICSS endpoint — the key inconsistency.
Panel auditInternal validity: high · scope of inference: Adults with DED and inferior corneal staining ≥0.5 at baseline; directly tests inferior corneal staining change vs placebo.Key limitations: co-primary sign endpoint not met · symptom endpoint met but sign endpoint null
No control group, staining is total corneal not inferior-specific, and the responder staining change was non-significant while overall signs did not change significantly.
Panel auditInternal validity: low · scope of inference: Moderate-to-severe DED subjects on lifitegrast over 12 weeks; cannot attribute any staining change to drug vs natural course.Key limitations: single-arm open-label · very small sample · not inferior-specific · staining change not significant
4 of 11 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Replicated positive pivotal RCT evidence on the exact endpoint supports the direction, but one well-powered null RCT on the same endpoint prevents a higher tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Unexplained pivotal-trial inconsistency. Two pivotal RCTs met the ICSS endpoint ([1], [11]) while [3] did not (P=0.6186); without a reconciling analysis the direct randomized evidence stays split on the exact endpoint. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An individual-participant-data meta-analysis across the pivotal trials, pre-specifying inferior corneal staining and testing baseline severity and population differences as effect modifiers.
Open question: Why did OPUS-2 [3] fail the inferior corneal staining endpoint while [1] and [11] met it? Why it is still open: The corpus records the conflicting pivotal results but no analysis reconciling the trials' populations, run-in design or baseline staining.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19